Apixaban in DVT prevention

Comparing the efficacy of apixaban vs enoxaparin in preventing venous thromboembolism after colorectal cancer surgery: A randomized control trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250204064643N1

Enrollment

176

Registered

2025-07-25

Start date

2025-08-23

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer. Malignant neoplasm of colon

Interventions

Intervention 1: Intervention group: Apixaaban 2.5mg twice daily for 4 weeks. Intervention 2: Control group: Enoxaparin 4000 IU daily for 4 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with an objective diagnosis of colorectal cancer, regardless of the stage of the disease Patients scheduled for elective laparotomy for colorectal cancer

Exclusion criteria

Exclusion criteria: Surgery for non-cancerous disease Known brain metastases Known hemorrhagic diathesis or high risk of bleeding History of intracerebral hemorrhage or neurosurgery within the past 6 months Renal failure defined as creatinine clearance <30 mL/min according to the Cockcroft Gault equation Hepatic failure Acute hepatitis Active chronic hepatitis Cirrhosis Alanine aminotransferase level 3 times or more above the upper limit of normal Bilirubin level twice the upper limit of normal or higher History of heparin-induced thrombocytopenia Age less than 18 years Pregnancy Breastfeeding Refusal of informed consent

Design outcomes

Primary

Measure	Time frame
Venous thromboemboli. Timepoint: Daily until discharge the on the days 14, 28 and 90. Method of measurement: History and Physical examination.;Ultrasound-confirmed deep vein thrombosis. Timepoint: Daily until discharge the on the days 14, 28 and 90. Method of measurement: Color Doppler ultrasound.;Severe bleeding within 28 ± 2 days (1 month) of planned laparotomy for colorectal cancer. Timepoint: within 28 ± 2 days (1 month) of planned laparotomy. Method of measurement: History and Physical examination.;Death within 28 ± 2 days (1 month) of planned laparotomy for colorectal cancer. Timepoint: Within 28 ± 2 days (1 month) of planned laparotomy. Method of measurement: Physical examination.	—

Measure

Time frame

Venous thromboemboli. Timepoint: Daily until discharge the on the days 14, 28 and 90. Method of measurement: History and Physical examination.;Ultrasound-confirmed deep vein thrombosis. Timepoint: Daily until discharge the on the days 14, 28 and 90. Method of measurement: Color Doppler ultrasound.;Severe bleeding within 28 ± 2 days (1 month) of planned laparotomy for colorectal cancer. Timepoint: within 28 ± 2 days (1 month) of planned laparotomy. Method of measurement: History and Physical examination.;Death within 28 ± 2 days (1 month) of planned laparotomy for colorectal cancer. Timepoint: Within 28 ± 2 days (1 month) of planned laparotomy. Method of measurement: Physical examination.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehzad Yaghoubi

Khoram-Abad University of Medical Sciences

behzad.yaghoubi@yahoo.com+98 66 3333 6141

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026